Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes loved the huge beat and raise, even better than I would have hoped. Still I think the full year Corti revenue guide is to low.
BB Second that. Lets see beat and raise Monday.
JTFM Thanks for sharing. I wonder why they have not issued a PR for this approval that was dated 5/1? Maybe they plan on the PR for Monday AM along with earnings release?
Nice find Auh2oman. This drug could give us a nice revenue boost this qtr. I already saw that MA and WA states are stocking up as well. I'm sure there are others.
The actual sell date on all of them was 3/7/23 at 44.23. To cover taxes per the notes.
Upgrade yesterday from Guggenheim to Buy with a $55.00 Price target.
Where were these guys back last June, when the SP hit $22. Corti projections
were out by then. I was buying more then.
The site wouldn't allow the SA link on this upgrade for some reason.
JTFM & Silvr, Thanks again for all the digging and sharing. Sounds great. It will be interesting to hear when mgt makes the public announcements about these in the future.
I agree. Lets hope this was a start of a major move this year!
Silvr, close to 52 week high SA lists their 52 week high at 45.05 in Jan last year. The stock has been and should continue to make steady gains throughout this year. Good luck to all.
Back to $40. + at open. Accumulation I believe is happening.
https://www.cytodyn.com/newsroom/press-releases/detail/606/
Blast from the past for all the old BioSante investors. Mr Stephen Simes has joined the BOD at CytoDyn Inc. I wasn't in BioSante back then. Any thoughts about him?
Nice bump this AM with their PR for release of Dexamethasone. A quick look on the web and it looks like there 6 other Companies that mfg Dexamethasone in the US and 9 more world wide.
https://seekingalpha.com/news/3873516-ani-pharmaceuticals-generic-dexamethasone-tablets-get-fda-approval?source=content_type%3Aall%7Cfirst_level_url%3Aportfolio%7Csection%3Aportfolio_content_unit%7Csection_asset%3Anews%7Cline%3A3
JTFM as always thanks for your research and response.
BB, I think today some of RJ's investors were listening. Nice pop up almost 6%!
Nice pop this AM up about 6%. Anyone see any news that might cause this?
Excellent post Misiu.
Silvr, I agree nice to see a steady progression on an almost daily basis, even on down Nasdaq days like today.
Thanks for the article. I like this line as well.
“Less than 10 percent of patients who could benefit from this therapy were benefited from it,” he noted. There may even be future indications that the drug could prove useful for, he said."
Art had talked about expanding the customer base for Corti. That was always the wild card that should come, to some degree with the large price reduction for the drug. Hopefully we get some comments on volume increases as well as forecasted revenue for the year, in the next CC.
Sounds interesting. Could be helpful down the road. Nice find.
Very nice insider action the last couple of days. "Many reasons to sell But only One reason to buy!"
JTFM, You maybe right about ANI trying to take advantage of their opportunities in Corti. As Elliot Wilbur alluded to in his second question about formulary placement;
"I mean, we're seeing Cortrophin placed on Tier 3 with prior authorization required similar to Acthar. And then we've seen it all the way down to where it's actually bumped Acthar from formulary altogether. Or where the payers are requiring step-through therapy with Cortrophin before patients can eventually get on Acthar, assuming that they do, which, obviously, is quite favorable for you guys."
Elliot obviously did his homework on Corti placement and coverage after launch. The same things that their competition already knows as well.
I was wondering why they made the statement about SG & A for Corti in 22 being between 42-45M. I would think even in their initial launch year they would feel they could at least double this number with revenue. If they did that 85-90M for 22, that would beat consensus revenue for the year by 45M at the low end of their guidance. What would that type of guidance do for the SP?
Very disappointed on how they issued the ER PR and the CC. Full year guidance does not include Corti revenue, They should have added that in the headline. Nikhil was very guarded about anything on Corti after launch in regards to pricing or marketing plan. It has been 6 weeks since the launch the competition ALREADY knows what they are doing, it would have been nice to let shareholders know some more details. They must have a pretty good idea by now as they plan to spend 42-46M on SG & A this year alone. The SP IMO, took most of this major hit based on this lack of understanding on Corti for 2022.
BB Q4 earnings call is Tuesday 3/15 at 8:30.
Yes you are right I was looking at the right month/day wrong year.
Yes very strange. I actually expected the PR for ER to be today. Last year they announced on 2/20 for ER on 2/27.
Labz, Good list. The only thing I would add, from my Business to Business experience, is that the First thing that any Company in Partnership or Buyout negotiations with CYDY would do, would be to sign an NDA. That NDA would likely have a gag order.
I wish they would include the revenue sharing part of the agreement (ie; 50/50) as well as the current market for the drugs. Previous PR's for other newly released drugs from them used to have that information.
New SA article from Bret Jensen today. https://seekingalpha.com/article/4485186-ani-pharmaceuticals-stock-back-buy-zone
Penny...Wrong ticker in article They have WRPT not WPRT. Try again.
Silvr, Yes nice bounce off that low. A good afternoon.
Yes I have made 2 additional buys recently. SP fluctuations keep on giving us nice opportunities to buy more IMO.
ANI just hit 50 again, lets hope for double that by this time next year. Merry Christmas to all and also a very Happy & Prosperous New Year!
LD, Good move after a crazy move in the SP. Btw I did the same.
Wow 90% drop, really? When do you think that will happen. Maybe if gold goes back to 1000.
Yup 10%+ drop way over reaction, that's why it's a good day to buy. I did buy more today.
Agree Pack10. Hard to believe you never hear the politicians or media even mention this or RNG at all.
Jtfm and Silvr sounds very promising! Maybe Explains the reason for the long timeline. Thanks for all your digging and sharing of your information.
As a longtime holder of ANI and ABBV, I certainly hope you are right.
Yesterday's closing price is only ~ 5% higher than the close the day before Corti was approved, crazy. I Bought more at 40, if you believe in Corti and the Novitium deal increasing profits and GM's over the next couple of years, this market reaction is just short term noise. If/when JTFM's theory on Libigel comes to fruition, we won't even recognize this Company in a couple of years.
Yes Like the full results from REVEAL 1 (in Dec) and announce full enrollment for REVEAL 2 (by EOY) for INO 3100!
Lakers, Thanks for posting. Did they also report the "P" values for these results?